Indybay newswire (Free subscription) | 09/06/2008
Contact for Kingdom Pipelines of South San Francisco, Subcontractor for the Li Ka-Shing Center for Biomedical and Health Sciences
eWhisper.net (Free subscription) | 09/06/2008
The AdWords Seminar for Success series is coming to San Francisco, CA. When: Tuesday, September 16 Where: Embassy Suites San Francisco Airpot 250 Gateway Boulevard South San Francisco, CA 94080 Agenda Timeline: Registration: 8:30 am – 9:00 am Morning Session: 9am-12pm Lunch Break: 12:00pm – 1:00pm Afternoon Session: 1pm-5pm Breakfast and refreshments will be served. Agenda: The Morning Session,...
Market Wire (Free subscription) | 09/05/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the initiation of its third Phase IIa clinical trial evaluating CK-1827452, a novel cardiac myosin activator being developed by the company for the potential treatment of patients with either acutely decompensated or chronic heart failure. CK-1827452 is the subject of a Collaboration and Option Agreement...
Market Wire (Free subscription) | 09/04/2008
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Theravance, Inc. (NASDAQ: THRX) today reported that an equity award was made to one new employee. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity award was granted under the Theravance, Inc. 2008 New Employee Equity Incentive Plan, which the Board of Directors of Theravance adopted to facilitate the granting of equity awards to new employees....
The Earth Times Online Newspaper (Free subscription) | 09/04/2008
SOUTH SAN FRANCISCO, CA -- 09/04/08 -- Theravance, Inc. (NASDAQ: THRX) today reported that an equity award was made to one new employee. Pursuant to Nasdaq Marketplace Rule 4350(i)(1)(A)(iv), the equity award was granted under the Theravance, Inc...
Baltimore Sun (Free subscription) | yesterday
Genentech is making no promises that it will act upon the trial's final results, which are expected in two to three years.The South San Francisco company has raised concerns that safety issues were not properly addressed. In particular, the trial doesn't have enough patients to show some of the rare but serious side effects that could occur with use of the cheaper drug, the company contends."No...
The San Francisco Business Times (Free subscription) | 09/05/2008
Cytokinetics Inc. started a third mid-stage clinical trial of a drug aimed at heart failure. (CYTK) (AMGN)
The San Francisco Business Times (Free subscription) | 09/05/2008
San Francisco-based SARcode will pay another milestone if the treatment makes it into a Phase II trial. Sunesis (NASDAQ: SNSS), based in South San Francisco, also got a $375,000 convertible note under this agreement.
bizjournals (Free subscription) | 09/05/2008
The South San Francisco company, a developer of integrated fluidic circuit systems that enable sophisticated biochemical measurements on nanoliter-scale liquid samples, plans to offer 5.3 million shares at a proposed range of $14-$16.
Fiercebiotech (Free subscription) | 09/03/2008
Anesiva is axing its preclinical development program as well as other "non-core positions" and reducing its head count by 20 percent as it restructures to focus on late-stage products and sales as the company makes its transition to a specialty pain management company. The South San Francisco biotech is also announced that it completed enrollment in two Phase III Adlea trials. Top-line data...
PR News Wire (Free subscription) | 09/05/2008
SOUTH SAN FRANCISCO, Calif., Sept. 5 /PRNewswire-FirstCall/ -- SARcode Corporation, a private company focused on small molecule LFA-1 inhibitors to treat inflammatory diseases, and Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced SARcode's initiation of a Phase 1 clinical trial of a small molecule LFA-1 product candidate for T-cell mediated ophthalmic diseases. Sunesis and SARcode entered...
San Fransisco Chronicle (Free subscription) | 09/03/2008
This Week's football games Thursday East Bay/Contra Costa Mt. Diablo vs. Irvington at Washington-Fremont, 7 p.m. Friday San Francisco/ Peninsula Nonleague South San Francisco at Carlmont, 3:15 p.m. Lincoln-SF at Gunn-Palo Alto, 7:30 p.m. Burlingame at Terra...
San Fransisco Chronicle (Free subscription) | 09/05/2008
A Roche Palo Alto spokeswoman said the 1-million-square-foot facility's inflammation research unit will move to Nutley, N.J., Roche's current U.S. headquarters.The company expects to move its Palo Alto virology operations to Genentech's nearby South San Francisco campus, though the unit would remain separate from the biotechnology giant.Spokeswoman Jacqueline Wallach said the timing of the closure,...
Fiercebiotech (Free subscription) | 09/02/2008
Palo Alto may have to say goodbye to as many as 3,000 jobs. According to the San Francisco Business Times , Roche is planning to move its inflammation business from Palo Alto to Nutley, NJ and its virology ops--also at Palo Alto--to South San Francisco. The company will also move U.S. pharmaceutical commercial operations from its New Jersey site to South San Francisco. "Roche is not...
Business Wire (Free subscription) | 09/03/2008
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cell Genesys, Inc. (Nasdaq:CEGE) today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will
